- Conditions
- Congestive Heart Failure
- Interventions
- Tolvaptan
- Drug
- Lead sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 170 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2004
- U.S. locations
- 35
- States / cities
- Tucson, Arizona • Little Rock, Arkansas • San Diego, California + 30 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 73–96
of 249
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Attention Deficit/Hyperactivity Disorder
- Interventions
- Centanafadine Hydrochloride
- Drug
- Lead sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Industry
- Eligibility
- 4 Years to 18 Years
- Enrollment
- 680 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 84
- States / cities
- Dothan, Alabama • Saraland, Alabama • Phoenix, Arizona + 62 more
- Conditions
- Bipolar Disorder
- Interventions
- Aripiprazole, Placebo
- Drug
- Lead sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 400 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2006
- U.S. locations
- 28
- States / cities
- Tuscaloosa, Alabama • Little Rock, Arkansas • San Diego, California + 25 more
- Conditions
- Bipolar Disorder
- Interventions
- aripiprazole
- Drug
- Lead sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 400 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2007
- U.S. locations
- 20
- States / cities
- Little Rock, Arkansas • Riverside, California • Deerfield Beach, Florida + 17 more
- Conditions
- Depressive Disorder, Depression, Depressive Disorder, Major, Mood Disorders, Mental Disorders
- Interventions
- Brexpiprazole, Seroquel XR, Placebo
- Drug
- Lead sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 2,182 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2016
- U.S. locations
- 44
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 39 more
- Conditions
- Healthy Volunteers, Drug Users
- Interventions
- EB-1020 400 mg, EB-1020 800 mg, lisdexamfetamine 150 mg, d-amphetamine 40 mg, Placebo
- Drug
- Lead sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Industry
- Eligibility
- 18 Years to 55 Years · Male only
- Enrollment
- 80 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014
- U.S. locations
- 1
- States / cities
- Overland Park, Kansas
- Conditions
- Phenylketonuria (PKU)
- Interventions
- JNT-517
- Drug
- Lead sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Industry
- Eligibility
- 4 Years and older
- Enrollment
- 240 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 8
- States / cities
- Gainesville, Florida • Tampa, Florida • Portland, Oregon + 4 more
- Conditions
- Neurobehavioral Disinhibition
- Interventions
- Placebo, AVP-786-28, AVP-786-42.63
- Drug
- Lead sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 168 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 54
- States / cities
- Tuscaloosa, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 45 more
- Conditions
- Acute Myeloid Leukemia
- Interventions
- Not listed
- Lead sponsor
- Center for International Blood and Marrow Transplant Research
- Network
- Eligibility
- Up to 21 Years
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2017
- U.S. locations
- 34
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Loma Linda, California + 29 more
- Conditions
- Depressive Disorder, Depression, Depressive Disorder, Major, Mood Disorders, Mental Disorders
- Interventions
- OPC-34712 + ADT, Placebo + ADT
- Drug
- Lead sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 826 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 37
- States / cities
- Arcadia, California • Beverly Hills, California • Fresno, California + 34 more
- Conditions
- Attention Deficit Disorder With Hyperactivity
- Interventions
- CTN SR, Matching placebo
- Drug
- Lead sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 85 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 4
- States / cities
- Newport Beach, California • Bradenton, Florida • Maitland, Florida + 1 more
- Conditions
- Depressive Disorder, Depression, Depressive Disorder, Major, Mood Disorders, Mental Disorders
- Interventions
- OPC-34712, Escitalopram, Fluoxetine, Paroxetine CR, Sertraline, Duloxetine, Venlafaxine XR
- Drug
- Lead sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 2,944 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2017
- U.S. locations
- 93
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 90 more
- Conditions
- Major Depressive Disorder
- Interventions
- Antidepressant + Aripiprazole
- Drug
- Lead sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,002 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2007
- U.S. locations
- 58
- States / cities
- Mesa, Arizona • Peoria, Arizona • Beverly Hills, California + 55 more
- Conditions
- Healthy Volunteer
- Interventions
- AVP-786, AVP-923
- Drug
- Lead sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 62 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2015
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Alcoholism
- Interventions
- Aripiprazole, Placebo
- Drug
- Lead sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Industry
- Eligibility
- 21 Years to 65 Years
- Enrollment
- 400 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2005
- U.S. locations
- 14
- States / cities
- Farmington, Connecticut • New Haven, Connecticut • Indianapolis, Indiana + 11 more
- Conditions
- Schizophrenia, Mental Disorder, Nervous System Diseases
- Interventions
- MIND1 System
- Device
- Lead sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 67 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 6
- States / cities
- Cerritos, California • Garden Grove, California • Oceanside, California + 3 more
- Conditions
- Adolescent Schizophrenia, Child or Adolescent Bipolar I Disorder, Manic or Mixed Episode With or Without Psychotic Features
- Interventions
- Aripiprazole
- Drug
- Lead sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Industry
- Eligibility
- 10 Years to 17 Years
- Enrollment
- 524 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2014
- U.S. locations
- 23
- States / cities
- Dothan, Alabama • Downey, California • Miami, Florida + 19 more
- Conditions
- Autosomal Dominant Polycystic Kidney Disease
- Interventions
- Tolvaptan MR, Tolvaptan IR
- Drug
- Lead sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Industry
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 6
- States / cities
- Boston, Massachusetts • Minneapolis, Minnesota • Rochester, Minnesota + 3 more
- Conditions
- Helicobacter Infection
- Interventions
- Standard Triple Therapy, Sequential Therapy
- Drug
- Lead sponsor
- Dallas VA Medical Center
- Federal
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 184 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2013
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Schizophrenia
- Interventions
- Aripiprazole depot 300 or 400 mg, Aripiprazole 10-30 mg orally, Aripiprazole depot 25 or 50 mg, Placebo depot, Placebo tablets
- Drug
- Lead sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 937 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2012
- U.S. locations
- 39
- States / cities
- Cerritos, California • Escondido, California • Garden Grove, California + 31 more
- Conditions
- Autosomal Dominant Polycystic Kidney Disease (ADPKD)
- Interventions
- Tolvaptan
- Drug
- Lead sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,083 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2016
- U.S. locations
- 38
- States / cities
- Mobile, Alabama • Peoria, Arizona • Tempe, Arizona + 33 more
- Conditions
- Schizophrenia
- Interventions
- SEP-363856
- Drug
- Lead sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Industry
- Eligibility
- 13 Years to 65 Years
- Enrollment
- 463 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 25
- States / cities
- Little Rock, Arkansas • Rogers, Arkansas • Anaheim, California + 19 more
- Conditions
- Ulcerative Colitis
- Interventions
- OPC-6535, Asacol®
- Drug
- Lead sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 1,725 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2007
- U.S. locations
- 26
- States / cities
- Huntsville, Alabama • Los Angeles, California • Hollywood, Florida + 23 more
- Conditions
- Schizophrenia, Schizoaffective Disorder
- Interventions
- Quetiapine or Risperidone + Aripiprazole, Quetiapine or Risperidone + placebo
- Drug
- Lead sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 323 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2007
- U.S. locations
- 48
- States / cities
- Little Rock, Arkansas • Cerritos, California • Costa Mesa, California + 37 more